- Open
- 8.85
- High
- 9.00
- Low
- 7.12
- Close
- 7.65
- Change
- -1.25 (-14.29%)
- Volume
- 10,986,732
⌘K
| 1 May 2026 | 07:00:05 | Q1 2026 Trading Update |
| 30 Apr 2026 | 07:01:01 | Total Voting Rights |
| 27 Apr 2026 | 07:00:10 | Enrollment in Phase II Clinical Trial for ACCRUFeR |
| 9 Apr 2026 | 12:30:28 | Audited results for year ended 31 December 2025 |
| 1 Apr 2026 | 09:22:08 | Publication of Report, Reinforcing FDA Approval |
| 6 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 22 May 2025 | Shield Therapeutics plc 2024 Annual Report and Accounts | |
| 17 Jun 2024 | Annual Report and Accounts (to 2023-12-31) |
| 30 Jan 2026 | Shield Therapeutics delivers more good news | |
| 30 Dec 2025 | Shield Therapeutics wins US extension | |
Shield is a specialty pharmaceutical company that operates in the commercial stage and is dedicated to tackling iron deficiency. Its flagship product, Accrufer/Feraccru, is an innovative, non-salt based oral treatment designed for adults suffering from iron deficiency, whether or not they have anaemia.
| 1 May 2026 | 07:00:05 | Q1 2026 Trading Update |
| 30 Apr 2026 | 07:01:01 | Total Voting Rights |
| 27 Apr 2026 | 07:00:10 | Enrollment in Phase II Clinical Trial for ACCRUFeR |
| 9 Apr 2026 | 12:30:28 | Audited results for year ended 31 December 2025 |
| 1 Apr 2026 | 09:22:08 | Publication of Report, Reinforcing FDA Approval |
| 6 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 22 May 2025 | Shield Therapeutics plc 2024 Annual Report and Accounts | |
| 17 Jun 2024 | Annual Report and Accounts (to 2023-12-31) |
| 30 Jan 2026 | Shield Therapeutics delivers more good news | |
| 30 Dec 2025 | Shield Therapeutics wins US extension | |
Shield is a specialty pharmaceutical company that operates in the commercial stage and is dedicated to tackling iron deficiency. Its flagship product, Accrufer/Feraccru, is an innovative, non-salt based oral treatment designed for adults suffering from iron deficiency, whether or not they have anaemia.
| 21 Nov 2024 |
| November 2024 Investor Forum |
| 11 Sept 2024 | Focusing on successful execution |
| 23 May 2024 | Cash management is key |
| 15 Nov 2023 | Accelerating effectiveness of enlarged sales team |
| 25 Jul 2023 | Accrufer Rx momentum gathering |
| 17 May 2023 | Reassuring 1Q’23 Accrufer prescriptions |
| 21 Nov 2024 |
| November 2024 Investor Forum |
| 11 Sept 2024 | Focusing on successful execution |
| 23 May 2024 | Cash management is key |
| 15 Nov 2023 | Accelerating effectiveness of enlarged sales team |
| 25 Jul 2023 | Accrufer Rx momentum gathering |
| 17 May 2023 | Reassuring 1Q’23 Accrufer prescriptions |